Oncology ยท Medical Literature
Prediction models for postoperative recurrence in papillary thyroid carcinoma: a systematic review and critical appraisal.
Abstract
Prediction models for postoperative recurrence in papillary thyroid carcinoma (PTC) have increased substantially in recent years. However, recurrence outcomes are inconsistently defined across studies, particularly with respect to structural and biochemical recurrence, and the quality and clinical applicability of existing models remain uncertain. To systematically review and critically appraise multivariable prediction models for structural postoperative recurrence in pathologically confirmed PTC and to evaluate their predictive performance, methodological quality, and risk of bias. PubMed, Embase, and the Cochrane Library were searched from inception to February 2026. Studies developing or validating multivariable prediction models for structural recurrence in adult patients with PTC were included. Data extraction was guided by the CHARMS checklist, and risk of bias was assessed using PROBAST. Findings were synthesized narratively, and an exploratory meta-analysis of discrimination performance from validation studies was conducted where appropriate. Thirteen retrospective studies met the inclusion criteria, all of which were conducted in East Asian populations. Reported discrimination was generally acceptable, with most AUC or C-index values exceeding 0.70. However, all studies were judged to have a high overall risk of bias, primarily due to limitations in the analysis domain, including inadequate handling of overfitting, insufficient sample size justification, limited reporting of missing data, and reliance on internal validation. Only two studies performed external validation. Exploratory pooling of validation AUCs suggested moderate predictive performance but substantial heterogeneity across studies. Current prediction models for structural recurrence in PTC show promise for individualized risk estimation but remain limited by methodological weaknesses, heterogeneous modelling approaches, inadequate assessment of calibration, and scarce external validation. Future studies should adopt standardized recurrence definitions, improve reporting transparency, and prioritize robust external validation before routine clinical implementation can be recommended.
Clinical relevance
Papillary thyroid carcinoma is the most common thyroid malignancy, and accurate postoperative recurrence risk stratification is essential for guiding surveillance intensity and adjuvant therapy decisions. This systematic review addresses a critical gap: despite a proliferation of prediction models, their methodological rigor and generalizability remain largely unvetted, leaving clinicians without reliably validated tools for individualized risk estimation. The findings are particularly timely given increasing reliance on risk-adapted management strategies in PTC, including active surveillance of low-risk disease and selective use of radioiodine ablation.
Key findings
1. Thirteen retrospective studies met inclusion criteria for multivariable prediction models of structural postoperative recurrence in pathologically confirmed PTC, all originating exclusively from East Asian populations, raising significant concerns about external generalizability to Western and ethnically diverse cohorts. 2. Discrimination performance was generally acceptable across studies, with most reported AUC or C-index values exceeding 0.70; however, exploratory meta-analysis of validation AUCs demonstrated only moderate pooled predictive performance with substantial heterogeneity across studies. 3. All 13 included studies were judged to carry a HIGH overall risk of bias per PROBAST (Prediction model Risk Of Bias ASsessment Tool), indicating that no currently published model meets the methodological threshold for confident clinical application. 4. The primary drivers of high risk of bias were located in the analysis domain: inadequate handling of overfitting, insufficient a priori sample size justification, limited reporting of missing data strategies, and over-reliance on internal validation methods. 5. Only 2 of 13 studies (approximately 15%) performed external validation, representing a critical deficiency in the evidence base for clinical translation of these models. 6. Recurrence outcomes were inconsistently defined across studies, particularly regarding the distinction between structural recurrence (imaging- or pathology-confirmed disease) and biochemical recurrence (thyroglobulin-based), undermining cross-study comparability and pooled analyses.
Practice implications
Clinicians should not adopt any currently published PTC postoperative recurrence prediction model into routine practice without external validation in their target population, as all reviewed models carry high risk of bias and were derived exclusively from East Asian cohorts with uncertain applicability to other populations. Until externally validated, risk stratification should continue to rely on established guideline-endorsed frameworks (e.g., ATA risk stratification, TNM staging) rather than novel nomograms or machine learning models lacking rigorous calibration data. Future institutional participation in prospective multicenter model validation studies using standardized structural recurrence definitions will be essential to accelerate the development of clinically deployable, bias-minimized prediction tools.